Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration
Michael Thomas,1 Shaymaa S Mousa,2 Shaker A Mousa1 1Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY, USA; 2The Johns Hopkins University, Baltimore, MD, USA Abstract: Wet age-related macular degeneration (AMD) is the most common reason for vision loss in...
Guardado en:
Autores principales: | Thomas M, Mousa SS, Mousa SA |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5781b0b02da84d49bbdfda4c510ada63 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical experience with fixed bimonthly aflibercept dosing in treatment-experienced patients with neovascular age-related macular degeneration
por: Khanani AM
Publicado: (2015) -
Treatment of neovascular age-related macular degeneration in patients with diabetes
por: Michael Cummings, et al.
Publicado: (2008) -
Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye
por: Hahn P
Publicado: (2014) -
Treatment of neovascular age-related macular degeneration: Current therapies
por: Albert J Augustin, et al.
Publicado: (2009) -
Role of pegaptanib sodium in the treatment of neovascular age-related macular degeneration
por: Sobha Sivaprasad
Publicado: (2008)